Revance Therapeutics Inc. (RVNC) Soars 5.4% on March 19

0
75
Revance Therapeutics Inc. (RVNC) Soars 5.4% on March 19


Revance Therapeutics Inc. (RVNC) had a good day on the market for Friday March 19
as
shares jumped 5.4% to close at $29.30. About 1.21 million shares traded hands on 5,900 trades for the day, compared with an average daily volume of
n/a shares out of a total float of 71.41 million. After opening the trading day at $27.75, shares of Revance Therapeutics Inc. stayed within a range of $29.43 to
$27.46.

With today’s gains, Revance Therapeutics Inc. now has a market cap of
$2.09 billion. Shares of Revance Therapeutics Inc. have been trading within a range of $34.62
and $12.00 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in research and development of aesthetic and therapeutic products.

Revance Therapeutics Inc. is based out of Nashville, TN and has some 470 employees. Its CEO is Mark J. Foley.

For a complete fundamental analysis of Revance Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for
RVNC.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Revance Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell
Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an
objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives
a broad, unbiased look at the small-cap market as a whole.


To get more information on Revance Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here:
RVNC’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE:
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Next page





Source link